NF-κB-IN-21

NF-κB-IN-21 (Compound 6e) (0.005-3.333 μM; 1 h) potently inhibits LPS-induced NO production in RAW264.7 cells with an IC₅₀ of 47.76 nM, while maintaining high cell viability at low concentrations^[1].
NF-κB-IN-21 (0.041-0.370 μM; 24 h co-incubation with LPS) inhibits LPS-induced activation of the NF-κB pathway in RAW264.7 cells in a dose-dependent manner by reducing the phosphorylation levels of IκBα and p65, and downregulates the expression of downstream iNOS^[1].
NF-κB-IN-21 inhibits LPS-induced nuclear translocation of p65 in RAW264.7 cells, confirming its inhibitory effect on the activation of the NF-κB pathway^[1].
NF-κB-IN-21 (0.005-3.333 μM; 24-72 h) shows no significant acute cytotoxicity in LO2 cells after 24 h of treatment, and its 72 h cytotoxicity (IC₅₀ = 6.557×10^-7 M) is comparable to that of Celastrol (HY-13067)^[1].
NF-κB-IN-21 (0.014-0.123 μM; 1 h pretreatment) potently and dose-dependently inhibits LPS-induced IL-6 production in RAW264.7 cells, while moderate inhibition of TNF-α is restricted to the highest tested concentration (0.123 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.